Provided vision and strategic direction, directing the identification of growth opportunities and innovation and a global portfolio of alliances and collaborations, fostering innovative partnerships.Analyzed external business landscapes, identified growth opportunities, and managed a comprehensive knowledge base. Led due diligence, presented findings to senior leadership. Contributed to complex deal negotiations of license and collaboration agreements, providing critical review, and influencing decision making. Oversaw alliance programs and governance of partnerships and launched new partnerships. Ensured seamless alignment across the value chain, optimized collaborations, and supported joint steering committees. Established robust partnership management processes, collaborated on supplier strategy, and resolved collaboration challenges.Selected Highlights:● Sourced and evaluated 100 partnership opportunities across neurology, ophthalmology, and oncology; performed due diligence and successfully executed opportunities in acute myeloid leukemia and gene therapy for CNS, resulting in signed contracts with external parties. ● Guided alliance program management in ophthalmology to complete IND enabling studies.● Led the termination process of a program, collaborating with the CSO and external stakeholders, ensuring an amicable severance. ● Resolved conflicts with a service contractor over quality of performance and oversaw the renegotiation and amendments of agreements.● Mentored junior associates, fostering a collaborative culture within the team and contributing to their professional development.

Analyzed and assessed two projects in ophthalmology and spinal cord injury, providing insights into early-stage VC decision-making. Assessed the work done under Kairos funding, collaborating with CROs and internal teams to compile comprehensive reports. Delivered decision-making recommendations based on the assessment of the project’s outcome and merit for further investment. Selected Highlights: ● Led the comprehensive assessment of preclinical proof-of-concept studies for small molecule drug development in ophthalmology, and gene therapy drug in spinal cord injury., influencing pivotal early-stage decisions. ● Delivered impactful recommendations based on the integration of internal and external data, guiding investment choices for projects in ophthalmology and spinal cord injury.

Founded and incorporated company developed business strategy and small molecule R&D programs; managed intellectual property and identified potential alliances and investors, including venture capital.

Led strategic planning prioritizing external partnerships with industry and developing market campaigns. Successfully identified and progressed business opportunities in cell therapies based on NYBC cord blood bank resources and CAR-T cell manufacturing capabilities. Mentored junior team members.Selected Highlights:● Led strategic business initiatives and twelve successful partnerships in oncology, infectious diseases, immunology, hematology, and closed academic and industry collaboration agreements with pharma. ● Oversaw market research, intellectual property protection, patent filing and prosecution of forty patent families.

Managed comprehensive deal-making processes, overseeing research collaborations, licensing,intellectual property, and venture investments at Mount Sinai. Coordinated stakeholders, unifying Mount Sinai's position on negotiations for large-scale deals, including licensing the Mount Sinai biobank to Regeneron for genetics drug discovery and development platforms. Led negotiations and closures of seven external research collaborations and licensing agreements, from initial outreach to finalizing the deals. Contributed to the launch of Sema4, a successful genomics and precision medicine startup.Selected Highlights:● Guided cross-functional teams in evaluating, negotiating, and closing a partnership agreement in precision medicine with Regeneron Genetics Center, enhancing Mount Sinai's presence in genetic treatment drug discovery.● Played a crucial role in the launch of Sema4, a successful genomics and precision medicine startup, providing legal audit support for service contracts, agreements, and intellectual property rights transfer.● Closed seven research collaborations and licensing agreements with pharmaceutical and biotech partners, demonstrating proficiency in negotiation and deal closure within the healthcare and life sciences sector.● Assessed research activities for patentability and directed domestic and international patent filing and IP prosecution.

Directed business development strategy and technology evaluation for multiple therapeutic areas. Negotiated and managed a comprehensive portfolio of about 500 agreements and led domestic and international patent filing and IP prosecution for over 200 patent families. Contributed to the launch of several startups.

Provided consulting services for Merrimack Pharmaceuticals, Inc.; Vanderbilt University; University of Cincinnati, Genome Research Institute; Yale; Mass General Hospital and Brigham and Women’s Hospital.

• Assessed and strategically prioritized partnerships and transactions• Structured, negotiated, and closed research agreements • Partnered with internal Legal/IP and built alliances with academic technology transfer offices • Managed alliances and new research projects • Identified, evaluated, and made recommendations for new R&D opportunities • Formulated template for research agreements with universities